Back to results
US 2018/0000828 A1Published application
Emulsion formulations of aprepitant
AssigneeHeron Therapeutics, Inc.
InventorsThomas B. Ottoboni, Han Han
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Claims22
A physically stable pharmaceutical composition, comprising:
- aprepitant;
- an emulsifier;
- an oil;
- and
- water;
- wherein the ratio of the emulsifier to aprepitant (wt %:wt %) ranges from about 18:1 to 22:1, wherein the ratio of the oil to aprepitant (wt %:wt %) ranges from about 11:1 to 15:1, and
- wherein the composition is an emulsion.
4 more elements
A physically stable pharmaceutical composition, comprising:
- aprepitant;
- egg yolk lecithin;
- soybean oil;
- and
- water;
- wherein the ratio of the egg yolk lecithin to aprepitant (wt %:wt %) is 20:1,
- wherein the ratio of soybean oil to aprepitant (wt %:wt %) is 13:1,
- wherein the composition is an emulsion.
5 more elements
Dependencies are inferred from the claim text.